Peripheral vertigo

disease

On this page

Summary

Peripheral vertigo (MONDO:0004900) is a disease with 6 GWAS associations across 6 studies and 3 clinical trials. Top therapeutic interventions include dimenhydrinate and sodium bicarbonate. A subtype of vestibular disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

GWAS associations: 6
Clinical trials: 3

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	peripheral vertigo
Mondo ID	MONDO:0004900
DOID	DOID:9847
SNOMED CT	50438001
UMLS	C0155501
MedGen	102334
Is cancer (heuristic)	no

Data availability: 6 GWAS associations (6 studies).

Disease family

This is a subtype of vestibular disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › auditory system disorder › inner ear disorder › vestibular disorder › peripheral vertigo

Subtypes (4): endolymphatic hydrops, vertigo, benign recurrent, 2, benign paroxysmal positional vertigo, vertigo, benign recurrent, 1

Genetics & variants

GWAS landscape

6 GWAS associations across 6 studies. Top hits map to 2 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
rs10862089	1e-30	OTOGL	G	0.24
rs426564	2e-29	ZNF91	G	0.14
chr19:23486668	5e-24		A	0.15
rs2980097	1e-12	TMEM128 - LYAR	C	0.09

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST90475907	Verma A	2024	13,472	421,612	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90477814	Verma A	2024	2,768	115,422	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90480112	Verma A	2024	2,768	115,422	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90475906	Verma A	2024	1,863	55,550	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90436046	Zhou W	2018	380	402,827	Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies.
GCST90043831	Jiang L	2021	284	456,064	A generalized linear mixed model association tool for biobank-scale data.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	1
Tier 2: splice/UTR	0
Tier 3: regulatory	0
Tier 4: intronic/intergenic	3

MAF distribution

Bucket	Variants
common (>=0.05)	4
low_freq (0.01-0.05)	0
rare (<0.01)	0
unknown	0

Functional consequences

Consequence	Count
intergenic_variant	2
missense_variant	1
unknown	1

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
rs10862089	12	80305695	G>T	0.081	missense_variant	OTOGL	1e-30	Tier 1: coding
rs426564	19	23314211	G>A,C	0.308	intergenic_variant	ZNF91	2e-29	Tier 4: intronic/intergenic
chr19:23486668				0.212			5e-24	Tier 4: intronic/intergenic
rs2980097	4	4251914	C>A,G	0.395	intergenic_variant	TMEM128 - LYAR	1e-12	Tier 4: intronic/intergenic

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 3.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE4	1
PHASE3	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01890538	PHASE4	COMPLETED	Comparison of Efficacy Between Piracetam and Dimenhydrinate in Patients With Peripheral Vertigo
NCT05586763	PHASE3	RECRUITING	Comparison of Efficacy of Metoclopramide , Promethazine and Prochloroperazine in the Treatment of Vertigo.
NCT05676216	Not specified	UNKNOWN	Sodium Bicarbonate for Acute Peripheral Vertigo

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
DIMENHYDRINATE	4	1
SODIUM BICARBONATE	4	1

Drugs: Dimenhydrinate, Sodium Bicarbonate